Urokinase biosimilar - Sedico

Drug Profile

Urokinase biosimilar - Sedico

Alternative Names: Angikinase

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Sedico
  • Class Plasminogen activator enzymes; Thrombolytics
  • Mechanism of Action Fibrinolytic agents; Plasmin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary thrombosis; Myocardial infarction; Pulmonary embolism; Thromboembolism

Most Recent Events

  • 03 Mar 2014 Launched prior to March 2014 for Coronary thrombosis in Egypt (Intracoronary)
  • 03 Mar 2014 Launched prior to March 2014 for Myocardial infarction in Egypt (Intracoronary)
  • 03 Mar 2014 Launched prior to March 2014 for Pulmonary embolism in Egypt (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top